Government Accountability Office will investigate potential abuses with Orphan Drug Act
Reports of five- and six-figure annual price tags for orphan drugs have concerned U.S. senators.
Widening the lens for rare disease and pediatric research
Of the 30 million Americans affected by rare diseases, more than half are children. It's a tough population to treat, but we can start with a simple two-part question: How is the disease affecting the child’s life and what can we do to make it better?
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
High drug price concerns spur request for GAO investigation of Orphan Drug Act
Sens. Orrin Hatch (R-Utah), Chuck Grassley (R-Iowa) and Tom Cotton (R-Arkansas.) raised the possibility that regulatory or legislative changes might be needed “to preserve the intent of this vital law” that gives drugmakers lucrative incentives to develop drugs for rare diseases.